Alpelisib

GMP
Synonyms: BYL-719 (Standard
GMP 级别的 Alpelisib(即 Alpelisib GMP,MS-Z07072)可用作细胞疗法中的辅助试剂,而 Alpelisib(BYL-719)是一种口服有效的 PI3Kα 选择性抑制剂,可阻断 PIP2 向 PIP3 的转化,进而抑制 PI3K/AKT/mTOR、MAPK/ERK、Notch 及 JAK-STAT 等通路,同时诱导细胞凋亡 (apoptosis)、G0/G1 期阻滞和衰老,并显著抑制肿瘤细胞的增殖、自我更新、干性及上皮-间质转化 (EMT),减少癌症干细胞群以降低干细胞标志物的表达;此外,它不仅能增强 Eribulin (MS-C96424) 的敏感性并与 Paclitaxel 产生协同作用,还可能通过上调 SGK3/GSK3β/β-连环蛋白信号通路引发耐药性,可应用于乳腺癌、胃癌以及 PTEN 错构瘤肿瘤综合征相关脂肪瘤的相关研究。
产品编号: MS-R67042 CAS No.: 1217486-61-7 分子式: C19H22F3N5O2S 分子量: 441.47
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

GMP 级别的 Alpelisib(即 Alpelisib GMP,MS-Z07072)可用作细胞疗法中的辅助试剂,而 Alpelisib(BYL-719)是一种口服有效的 PI3Kα 选择性抑制剂,可阻断 PIP2 向 PIP3 的转化,进而抑制 PI3K/AKT/mTOR、MAPK/ERK、Notch 及 JAK-STAT 等通路,同时诱导细胞凋亡 (apoptosis)、G0/G1 期阻滞和衰老,并显著抑制肿瘤细胞的增殖、自我更新、干性及上皮-间质转化 (EMT),减少癌症干细胞群以降低干细胞标志物的表达;此外,它不仅能增强 Eribulin (MS-C96424) 的敏感性并与 Paclitaxel 产生协同作用,还可能通过上调 SGK3/GSK3β/β-连环蛋白信号通路引发耐药性,可应用于乳腺癌、胃癌以及 PTEN 错构瘤肿瘤综合征相关脂肪瘤的相关研究。

生物实验数据

生物活性 Alpelisib GMP is the GMP-grade form of Alpelisib (MS-Z07072), and GMP-grade small molecules can be used as auxiliary reagents in cell therapy; Alpelisib (BYL-719) is an orally active, selective PI3Kα inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways such as PI3K/AKT/mTOR, MAPK/ERK, Notch, and JAK-STAT, and it also induces apoptosis, G0/G1 phase arrest, and senescence, while significantly inhibiting tumor cell proliferation, self-renewal, stemness, and epithelial-mesenchymal transition (EMT), reducing the cancer stem cell population to decrease the expression of stem cell markers; moreover, it not only enhances the sensitivity of Eribulin (MS-C96424) and produces synergistic effects with Paclitaxel, but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway, and it can be applied to research related to breast cancer, gastric cancer, and lipomas associated with PTEN hamartoma tumor syndrome.
IC50 & Target p110α-H1047R:4 nM, p110δ:290 nM, p110γ:250 nM (cell free), p110α:5 nM (cell free), p110α-E545K:4 nM, p110β:1200 nM
体外研究
(In Vitro)

Alpelisib GMP (0-5 μM; 14 d) 在 2D 克隆形成实验中可显著抑制 MCF-7 和 T47D 乳腺癌细胞的克隆生长。
Alpelisib GMP (5 μM; 5 d) 可剂量依赖性降低 MCF-7 和 T47D 类乳腺癌干细胞 (BCSC-like) 的乳腺球形成效率。
Alpelisib GMP (0-10 μM; 10 d) 可显著缩小 3D 培养体系中 MCF-7 和 T47D 类乳腺癌干细胞 (BCSC-like) 的球状体直径,抑制干细胞特性与耐药性。
Alpelisib GMP (1 μM; 24 h) 可显著降低 MCF-7 和 T47D 类乳腺癌干细胞 (BCSC-like cells) 中干细胞标志物 Nanog、Sox2 及 OCT3/4 的蛋白水平。
Alpelisib (10 μM; 10 d) 可抑制脂肪生成,从而减弱 2D 培养体系中 LipPD1 原发性脂肪瘤细胞的脂肪细胞分化,并缩小 3D LipPD1 脂肪瘤球的体积。
Alpelisib GMP (10 μM; 4 d) 与 1 μM SGK3 抑制剂 (VPS34-IN1 (MS-H71066) 或 SGK3-IN) 联合使用,在对 Alpelisib GMP 耐药的 MCF7R 和 T47DR 乳腺癌细胞中产生增强的抗增殖活性,其中 Alpelisib+SGK3-IN 组合观察到协同效应。

Cell Viability Assay

Cell Line: human MCF-7 breast cancer monolayer cells, MCF-7 breast cancer stem cell (BCSC)-enriched mammosphere cells, human T47D breast cancer monolayer cells, T47D BCSC-enriched mammosphere cells
Concentration: Serial dilutions
Incubation Time: 96 h
Result: Inhibited cell viability in a dose-dependent manner.
Achieved an IC50 of 0.225 μM in MCF-7 monolayer cells.
Achieved an IC50 of 0.453 μM in MCF-7 BCSC-enriched mammosphere cells.
Achieved an IC50 of 3.055 μM in T47D monolayer cells.
Achieved an IC50 of 5.105 μM in T47D BCSC-enriched mammosphere cells.

Cell Proliferation Assay

Cell Line: LipPD1, LipPD2, LipPD3 primary lipoma cells
Concentration: 1-100 µM
Incubation Time: 24-144 h
Result: Attenuated growth of all three lipoma cell cultures alone and in combination with rapamycin.
Maintained stable cell count for 6 days in LipPD1 cells treated with 100 µM.
Exhibited IC50 values for 72 h Hoechst assays of 15.91 µM (LipPD1), 10.06 µM (LipPD2), and 15.79 µM (LipPD3).
Reduced the fraction of Ki-67 positive LipPD1 cells in a concentration-dependent manner: to 0.75 fold (1 µM, p=0.074), 0.55 fold (10 µM, p=0.018), and 0.22 fold (100 µM, p=0.017).

Apoptosis Analysis

Cell Line: LipPD1, LipPD2, LipPD3, Lip3, Lip4 primary lipoma cells
Concentration: 50 µM
Incubation Time: 24, 72 h
Result: Observed no cell death after 72 h 50 µM treatment in LipPD1 and Lip3 cells.
Detected a slight reduction in viable cells in Lip4 cells.
Detected no additional LDH release in LipPD1, LipPD2, or LipPD3 cells after 24 h or 72 h 50 µM treatment, indicating no induction of cell death.

Western Blot Analysis

Cell Line: LipPD1 primary lipoma cells
Concentration: 10-100 µM
Incubation Time: 24, 48 h
Result: Reduced AKT activation (phospho-Thr 308) in 50 µM treated cells.
Reduced mTOR activation (phospho-Ser 2448) in 10 µM and 50 µM treated cells.
Significantly reduced phosphorylation of S6 (phospho-Ser 235/236) for all tested concentrations.
Reduced the fraction of pS6 positive LipPD1 cells to 0.57 fold (10 µM) and 0.01 fold (100 µM).

Cell Differentiation Assay

Cell Line: LipPD1 primary lipoma cells
Concentration: 10 µM
Incubation Time: 10 days
Result: Reduced lipid accumulation in 2D culture, with the fraction of adipocytes decreasing from 54.8% to 29.9%.
Downregulated mRNA expression of differentiation markers: PPARγ to 0.55 fold, adiponectin to 0.54 fold, aP2 to 0.54 fold, and FASN to 0.58 fold.
Reduced 3D spheroid size to 0.78 fold after 4 days and 0.79 fold after 10 days, with significant differences from day 4 onward, while control spheroid size increased to 1.25 fold after 10 days.
体内研究
(In Vivo)

Alpelisib GMP (50 mg/kg;腹腔注射;每日) 对 Alpelisib 耐药的 MCF7R 乳腺癌异种移植物发挥部分抗肿瘤活性,与 SGK3 敲低联合使用时可达到最大疗效。
Alpelisib GMP (50 mg/kg;腹腔注射;每日给药) 对 Alpelisib 耐药的 T47DR 乳腺癌异种移植物发挥部分抗肿瘤活性,与 SGK3 敲低联合使用时可达到最大疗效。
Alpelisib GMP (25 mg/kg;口服;每日一次;持续 4 周) 可在 PIK3CA 突变型胃癌异种移植模型中显著抑制肿瘤生长、降低肿瘤细胞增殖并促进肿瘤细胞凋亡,且经处理的小鼠在 4 周内的存活率达 100%。

Animal Model: BALB/c nude (6-week-old female)
Dosage: 50 mg/kg
Administration: i.p.; daily
Result: Exerted partial inhibition of MCF7R xenograft tumor growth.
Achieved maximum tumor growth inhibition when combined with SGK3 knockdown, with significantly reduced final tumor volumes and weights compared to vehicle control or SGK3 knockdown alone.\nExerted partial inhibition of T47DR xenograft tumor growth.
Achieved maximum tumor growth inhibition when combined with SGK3 knockdown, with significantly reduced final tumor volumes and weights compared to vehicle control or SGK3 knockdown alone.
Animal Model: Balb/c athymic nude mice (female, 5 weeks old, 26-28 g, subcutaneous xenograft of luciferase-expressing PIK3CA-mutant MKN1 human gastric cancer cells)
Dosage: 25 mg/kg
Administration: p.o.; daily; 4 weeks
Result: Significantly retarded tumor growth compared to the control group.
Decreased Ki-67 expression (proliferation marker).
Increased TUNEL expression (apoptosis marker).
Maintained stable body weight over the 4-week period.
Achieved 100% survival of treated mice over the 4-week period.

化学信息

分子量 441.47
分子式 C19H22F3N5O2S
CAS No. 1217486-61-7
别名 BYL-719 (Standard

储存&溶解度

溶解度信息
DMSO: 240 mg/mL (543.64 mM), Sonication is recommended.
Ethanol: 2 mg/mL (4.53 mM), Sonication is recommended.
体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 8.2 mg/mL (18.57 mM), Suspension.
10% DMSO+40% PEG300+ 5% Tween 80 + 45% Saline: 10 mg/mL (22.65 mM), Solution.
10% DMSO+90% Saline: < 10 mg/mL (22.65 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础